Clinical trials
Diabetes Complications trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
9 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2016 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 3 |
| Recruiting | 3 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Affiliated Hospital of Nantong University | 1 |
| Minghui Wang | 1 |
| Ningbo Eye Hospital | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Second Xiangya Hospital of Central South University | 1 |
| Shaanxi Provincial People's Hospital | 1 |
| Shanghai Zhongshan Hospital | 1 |
| The First Affiliated Hospital of Xiamen University | 1 |
| Wyeth is now a wholly owned subsidiary of Pfizer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Complications | 9 |
| Diabetes Mellitus | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Cardiovascular Diseases | 2 |
| Bacterial Infections | 1 |
| Cellulitis | 1 |
| Cerebrovascular Disorders | 1 |
| Coronary Artery Disease | 1 |
| Diabetic Foot | 1 |
| Diabetic Retinopathy | 1 |
Trials
Showing 76 to 9 of 9. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.